Collegium Pharmaceutical (NASDAQ:COLL) Research Coverage Started at Leerink Partners

Leerink Partners assumed coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $45.00 target price on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Barclays decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 19th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Needham & Company LLC reduced their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $22.75 on Wednesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. The business’s fifty day moving average price is $30.53 and its two-hundred day moving average price is $33.52. The stock has a market cap of $740.74 million, a PE ratio of 18.35 and a beta of 0.72. Collegium Pharmaceutical has a one year low of $22.64 and a one year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same period in the previous year, the firm posted $1.68 earnings per share. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, analysts forecast that Collegium Pharmaceutical will post 6.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC increased its holdings in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Collegium Pharmaceutical by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after buying an additional 4,625 shares during the period. Jane Street Group LLC raised its position in shares of Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after buying an additional 90,255 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock valued at $2,131,000 after acquiring an additional 2,592 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.